April 2012

In this interview, Lance A. Liotta, MD, PhD, discusses the hypothosis that led to the study and the research thus far into chloroquine.

Three prominent breast cancer clinicians and researchers share their opinions on adjuvant anthracyclines, fluoropyrimidines, and taxane agents for women with early breast cancer.

The neoadjuvant administration of sipuleucel-T may stimulate an immune response in patients with localized prostate cancer without adversely affecting their surgeries.

In a six-week span, José Baselga, MD, PhD, notched a stunning series of milestones in breast cancer research that could potentially change practice in different subtypes of the disease.

J. Michael Dixon, MBChB, MD, and Patrick I. Borgen, MD, discuss the pros and cons of long-term clinical follow-up care of patients with breast cancer.

Vemurafenib continues to demonstrate clinical response and overall survival benefits for patients with metastatic melanoma.

William G. Wierda, MD, PhD, discussed the management of chronic lymphocytic leukemia at the 16th Annual International Congress on Hematologic Malignancies.

Despite initial disappointing findings on overall survival, PARP inhibitors remains under active investigation for patients with ovarian cancer.

Cutaneous melanoma is becoming increasingly common in young adults, with an 8-fold increase among young adult females and a 4-fold increase among young adult males.

Leonard M. Neckers, PhD, has been studying the role of the molecular chaperone Hsp90 in signal transduction and the translational development of Hsp90-targeted anticancer agents for two decades.

Hsp90 may be referred to as the 'guardian of the proteome,' since it regulates the correct structure and function of many of the important proteins encoded by our DNA.

A retrospective analysis of the risks of hypothyroidism in patients who received sunitinib and sorafenib is gaining attention in the field of head and neck cancers.

The prognosis for a significant fraction of DLBCL patients that relapse while receiving the current standard treatment of R-CHOP-21 remains poor.

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.